Nonetheless, IGFBP-7 could be a promising biomarker in the context of depression, since IGFBP-7 has been proposed as a potential therapeutic target in Alzheimer’s disease [68], for which depression is a risk factor [79]. Here, IGFBP7 is linked to early-onset autosomal dominant Alzheimer disease.